Schwab U.S. Dividend Equity ETF (SCHD) offers a notably low expense ratio of 0.06%, making it one of the most cost-efficient dividend-focused ETFs in the market. By comparison, many peers charge fees of 0.20% or higher. SCHD currently delivers a 3.8% dividend yield, substantially exceeding the 1.2% yield of the S&P 500 index and outpacing several dividend-growth ETFs that prioritize dividend increases over current income. On a $100 investment, investors pay just six cents per year in fees to SCHD’s manager, enhancing net income for those seeking regular distributions.

Launched in October 2011, SCHD tracks the Dow Jones U.S. Dividend 100 Index, comprising 102 large-cap U.S. stocks selected for dividend sustainability and financial strength. Sector weights skew toward energy (19.3%), consumer staples (18.5%) and healthcare (16.1%). Top holdings include Bristol Myers Squibb, Merck & Co. and ConocoPhillips. Over the past five years, SCHD achieved a total-return growth of $1,000 to approximately $1,298, with a maximum drawdown of roughly 16.8%, closely mirroring broader market downturns while delivering higher income. Assets under management stand at $72.5 billion, reflecting strong investor demand for its blend of yield and quality.

In its latest Form 13F filing, Charles Schwab Trust Bank reduced its SCHD position by 43.6% during the third quarter, selling 1,562,608 shares and holding 2,017,759 shares valued at $55.1 million. Despite this reduction, SCHD remains the largest position in the bank’s portfolio, accounting for 100% of its ETF holdings. Other institutional investors—such as Lederer & Associates Investment Counsel, Madden Advisory Services and Bellevue Asset Management—made modest increases ranging from 0.3% to 4.8% in the same period, underscoring ongoing confidence in SCHD’s low-cost dividend strategy.